Consistent with this finding, the increase in CD4 counts among patients who did not stop treatment and who ended up below detection level averaged 238 cells/μl in the B-subtype group, 262 in the non-BC and only 179 cells/μl in the C group (p = 0.08 and 0.03, respectively). Here, CD4 is linked to breast cancer.